Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
INC Research Holdings Inc is a diagnostics & research business based in the US. INC Research shares (SYNH) are listed on the NASDAQ and all prices are listed in US Dollars. INC Research employs 26,751 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $71.57 |
|---|---|
| 52-week range | $62.28 - $104.18 |
| 50-day moving average | $70.87 |
| 200-day moving average | $85.09 |
| Wall St. target price | $93.90 |
| PE ratio | 30.9827 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $2.31 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $71.57 from 2022-07-01
| 1 week (2022-06-28) | 0.14% |
|---|---|
| 1 month (2022-06-01) | -0.82% |
| 3 months (2022-04-05) | -12.19% |
| 6 months (2022-01-05) | -23.71% |
| 1 year (2021-07-02) | -20.03% |
|---|---|
| 2 years (2020-07-02) | 24.40% |
| 3 years (2019-07-05) | 41.28% |
| 5 years (2017-07-05) | 24.42% |
Valuing INC Research stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of INC Research's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
INC Research's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 31x. In other words, INC Research shares trade at around 31x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
INC Research's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.1872. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into INC Research's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
INC Research's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $673.2 million.
The EBITDA is a measure of a INC Research's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $5.3 billion |
|---|---|
| Operating margin TTM | 8.11% |
| Gross profit TTM | $1.2 billion |
| Return on assets TTM | 3.33% |
| Return on equity TTM | 7.41% |
| Profit margin | 4.54% |
| Book value | $32.19 |
| Market capitalisation | $7.3 billion |
TTM: trailing 12 months
We're not expecting INC Research to pay a dividend over the next 12 months.
Over the last 12 months, INC Research's shares have ranged in value from as little as $62.28 up to $104.18. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while INC Research's is 1.7868. This would suggest that INC Research's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development. This segment also provides individual services, including product development and regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health, clinical trial diversity, biometric, and regulatory affair services. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication services; and consulting services to the pharmaceutical, biotechnology, and healthcare industries. The company was formerly known as INC Research Holdings, Inc.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
